Novo Nordisk will begin offering discounted subscription plans for U.S. patients who pay out of pocket for Wegovy, the Danish drugmaker said, marking a strategic push to widen access and regain competitive footing against Eli Lilly in the fast-growing obesity treatment market.
The new offering, available from Tuesday through selected telehealth platforms, allows eligible self-pay patients to purchase three-, six- or 12-month supplies at a fixed monthly cost. Longer subscription commitments produce larger per-month savings compared with the standard self-pay price.
Under the programme, Wegovy injection pens are priced at $329 per month for a three-month plan, $299 per month for a six-month plan and $249 per month for a 12-month subscription. Those prices represent discounts of about 6% to 29% versus the prevailing $349 monthly self-pay rate. For the Wegovy pill, the subscription tiers are $289, $269 and $249 per month respectively, which are roughly 3% to 17% below the standard $299 monthly cost.
Initially, the subscription service will be offered through telehealth partners Ro, WeightWatchers and LifeMD, with Hims & Hers, Sesame and additional telehealth companies expected to join soon, Novo said.
Executives at Novo framed the move as a response to changing consumer expectations. Ed Cinca, senior vice president of marketing and patient solutions at Novo, said people are seeking "easier and clearer ways of facilitating payment" as they pursue obesity management. "We’re seeing the patient evolving into the consumer of health," he added, noting that those paying out of pocket prefer straightforward budgeting, clear pricing and simpler ways to remain on therapy.
The subscription rollout comes amid intensifying efforts by both Novo Nordisk and Eli Lilly to reach patients directly through telehealth and company-led distribution channels, rather than relying solely on traditional insurance and physician office pathways. That direct-to-consumer push is intended to attract patients away from compounded generic copies and to improve continuity of treatment, even as deeper discounts pressure margins.
Industry participants have noted that both drugmakers are experimenting with new distribution and pricing models. Zach Reitano, CEO of telehealth partner Ro, said the companies are trying different approaches to reach consumers, lowering price points for the medicines and the costs of getting them to patients. "They’re following the exact same path that you’d normally see in other consumer industries," Reitano said.
Analysts and investors have cautioned that aggressive price competition carries risk for manufacturers. Some market observers say Novo has cut prices more steeply than Lilly in efforts to revive Wegovy prescriptions, which had lagged behind Lilly’s competing product Zepbound.
Lilly currently lists self-pay prices for Zepbound starting at $299 per month for the 2.5 mg dose, $399 for 5 mg and $449 for the 7.5 mg dose and higher under its Self Pay Journey Program. Lilly's oral obesity medicine is under review by the U.S. Food and Drug Administration, with the company expecting approval in the second quarter; earlier reporting suggested approval could occur in April.
Novo has recently made broader structural changes as it seeks to sharpen its U.S. competitiveness. Last year the company replaced its CEO, announced substantial job cuts and appointed a new head of its U.S. business as it adapts to a marketplace where rivals have moved quickly into direct-to-consumer sales.
Separately, Novo reduced Wegovy’s standard self-pay monthly price in November to $349 from $499, a roughly 30% drop, after running a temporary $199 starter-dose promotion. The new subscription programme builds on that pricing trajectory and on the company’s increasing reliance on telehealth and direct distribution to connect with patients who pay without insurance coverage.
Impacted sectors include pharmaceuticals, telehealth services and retail distribution for specialty medicines, as firms adapt pricing and channel strategies to retain patients and steer them toward branded, FDA-approved therapies.